My IDSA Contact Us
IDSA NewsPrint-Friendly Newsletter
Forward to a Friend
Search Back Issues
 
Education & Training Resources Practice Guidelines Journals & Publications Policy & Advocacy Meetings About IDSA
July/August 2015
PATIENT CARE AND SCIENCE
FDA Approves Technivie in Combination with Ribavirin for Treatment of HCV
The U.S. Food and Drug Administration recently approved Technivie (ombitasvir, paritaprevir and ritonavir) for use in combination with ribavirin for the treatment of hepatitis C virus (HCV) genotype 4 infections in patients without scarring and poor liver function (cirrhosis). Technivie in combination with ribavirin is the first drug that has demonstrated safety and efficacy to treat genotype 4 HCV infections without the need for co-administration of interferon, an FDA-approved drug also used to treat HCV infection.

IDSA offers two email services to help members stay informed of updates from FDA and the Centers for Disease Control and Prevention (CDC). Content includes a range of topics, including drug warnings, recalls, and outbreak investigations. Recent alerts have included:

Gilenya (fingolimod): Drug Safety Communication - FDA Warns About Cases of Rare Brain Infection (August 4, 2015)

Kaletra (lopinavir/ritonavir) product labeling updated (June 30, 2015)

Clinical Considerations for the Evaluation of Ill Travelers from Liberia to the United States (June 24, 2015)

Updated Information and Guidelines for Evaluation of Patients for MERS-CoV Infection (June 12, 2015)

IDSA members can sign up for these services online. (To subscribe, check the appropriate boxes to receive CDC’s Health Alert Network [HAN] messages and/or alerts from FDA, and provide your email address and name where indicated.)

Is Your Facility Experiencing Antibiotic Shortages?
IDSA members are urged to report drug shortages directly to FDA and to copy IDSA staff at schang@idsociety.org.



< Previous Article | Next Article >

Post a comment

Your name:

Your comment:


PATIENT CARE AND SCIENCE
Guideline on Diagnosis and Management of Vertebral Osteomyelitits Released
CDC Updated Guidelines on Treatment of Sexually Transmitted Diseases
FDA Approves Technivie in Combination with Ribavirin for Treatment of HCV
CLINICAL PRACTICE MANAGEMENT
CMS Issues FAQ Document on ICD-10 Implementation
POLICY AND ADVOCACY
White House Releases Five-Year HIV/AIDS Strategy
21st Century Cures Act Progresses Through Congress
House, Senate Committees Recommend 2016 Funding to Address Antibiotic Resistance
News from CDC: Recognizing the 20th Anniversary of the Emerging Infections Program
NIH Requests Input on its Strategic Plan
IDSA Comments on Criteria for $20 Million CARB Diagnostics Challenge
FDA Proposal Would Yield Better Data on Antibiotics in Meat, Poultry
GLOBAL ID
Science Speaks Covers 8th International AIDS Conference
EDUCATION AND RESOURCES
What Not to Miss at IDWeek 2015
OFID Offers Special Peer Review Track for Fellows of IDSA (FIDSA)
Latest OFID Podcast Features Martin Blaser on the Microbiome
YOU AND YOUR COLLEAGUES
FIDSA Designees Announced: 113 Distinguished Physicians, Scientists Honored
Members on the Move
Member Report
From the President
Setting IDSA’s Course to Lead the Future of ID
TOP STORIES
IDSA Compensation Survey: Take 5 Minutes to Help Us Advocate for You
Take Part in IDSA’s Future: Cast Your Vote in Board Elections
Journal Club
IDSA | 1300 Wilson Blvd., Suite 300 | Arlington, VA 22209 | Phone: (703) 299-0200
To ensure delivery, please add 'info@idsociety.org' to your email address book or Safe Sender List.
If you are still having problems receiving our communications,
see our white-listing page for more details.